Androgen Antagonists

"Androgen Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Compounds which inhibit or antagonize the biosynthesis or actions of androgens.

Descriptor ID	D000726
MeSH Number(s)	D06.347.065 D27.505.696.399.450.065
Concept/Terms	Androgen Antagonists Androgen Antagonists Antagonists, Androgen Antiandrogens Anti-Androgen Effect Anti-Androgen Effect Anti Androgen Effect Effect, Anti-Androgen Antiandrogen Effect Effect, Antiandrogen Antiandrogen Effects Effects, Antiandrogen Anti-Androgen Effects Anti Androgen Effects Effects, Anti-Androgen

Below are MeSH descriptors whose meaning is more general than "Androgen Antagonists".

Chemicals and Drugs [D]
Hormones, Hormone Substitutes, and Hormone Antagonists [D06]
Hormone Antagonists [D06.347]
Androgen Antagonists [D06.347.065]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Physiological Effects of Drugs [D27.505.696]
Hormones, Hormone Substitutes, and Hormone Antagonists [D27.505.696.399]
Hormone Antagonists [D27.505.696.399.450]
Androgen Antagonists [D27.505.696.399.450.065]

Below are MeSH descriptors whose meaning is related to "Androgen Antagonists".

Below are MeSH descriptors whose meaning is more specific than "Androgen Antagonists".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Androgen Antagonists" by people in this website by year, and whether "Androgen Antagonists" was a major or minor topic of these publications.

Bar chart showing 15 publications over 11 distinct years, with a maximum of 3 publications in 2013

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2003	1	0	1
2005	1	1	2
2007	1	0	1
2012	0	1	1
2013	2	1	3
2014	0	1	1
2015	1	0	1
2016	1	0	1
2019	0	1	1
2021	0	1	1
2022	0	2	2

Below are the most recent publications written about "Androgen Antagonists" by people in Profiles.

M?nguez-Alarc?n L, Burns J, Williams PL, Korrick SA, Lee MM, Bather JR, Kovalev SV, Sokolov SA, Lebedev AT, Smigulina L, Ghayda RA, Koch HM, Sergeyev O, Hauser R. Urinary phthalate metabolite concentrations during four windows spanning puberty (prepuberty through sexual maturity) and association with semen quality among young Russian men. Int J Hyg Environ Health. 2022 06; 243:113977.

View in: PubMed
Burns JS, Sergeyev O, Lee MM, Williams PL, M?nguez-Alarc?n L, Plaku-Alakbarova B, Sokolov S, Kovalev S, Koch HM, Lebedev AT, Hauser R, Korrick SA. Associations of prepubertal urinary phthalate metabolite concentrations with pubertal onset among a longitudinal cohort of boys. Environ Res. 2022 09; 212(Pt A):113218.

View in: PubMed
Nigro MC, Mollica V, Marchetti A, Cheng M, Rosellini M, Montironi R, Cheng L, Massari F. Current androgen receptor antagonists under investigation for resistant prostate cancer. Expert Rev Anticancer Ther. 2022 Feb; 22(2):191-202.

View in: PubMed
Lau HD, Clark M. Metastatic squamous cell carcinoma transformed from prostatic adenocarcinoma following androgen deprivation therapy: A case report with clinicopathologic and molecular findings. Diagn Cytopathol. 2020 Dec; 48(12):E14-E17.

View in: PubMed
Di Nunno V, Santoni M, Gatto L, Mollica V, Massari F. Re: Christopher C. Parker, Nicholas D. James, Christopher D. Brawley, et al. Radiotherapy to the Primary Tumour for Newly Diagnosed, Metastatic Prostate Cancer (STAMPEDE): A Randomised Controlled Phase 3 Trial. Lancet 2018;392:2353-66: Metastatic Hormone-na?ve Prostate Cancer: A Multimodal Approach for a Heterogeneous Disease. Eur Urol Oncol. 2020 06; 3(3):390.

View in: PubMed
Ciccarese C, Santoni M, Massari F. Chemohormonal Therapy in Hormone-Sensitive Prostate Cancer. N Engl J Med. 2016 01 21; 374(3):286.

View in: PubMed
Nguyen PL, Jarolim P, Basaria S, Zuflacht JP, Milian J, Kadivar S, Graham PL, Hyatt A, Kantoff PW, Beckman JA. Androgen deprivation therapy reversibly increases endothelium-dependent vasodilation in men with prostate cancer. J Am Heart Assoc. 2015 Apr 20; 4(4).

View in: PubMed
Parekh A, Chen MH, Graham P, Mahal BA, Hirsch AE, Nakabayashi M, Evan C, Kantoff PW, Martin NE, Nguyen PL. Role of androgen deprivation therapy in early salvage radiation among patients with prostate-specific antigen level of 0.5 or less. Clin Genitourin Cancer. 2015 Feb; 13(1):e1-6.

View in: PubMed
Ko EC, Liu JT, Stone NN, Stock RG. Association of early PSA failure time with increased distant metastasis and decreased survival in prostate brachytherapy patients. Radiother Oncol. 2014 Feb; 110(2):261-7.

View in: PubMed
Parekh A, Chen MH, D'Amico AV, Dosoretz DE, Ross R, Salenius S, Graham PL, Beckman JA, Beard CJ, Choueiri TK, Ennis RD, Hoffman KE, Hu JC, Ma J, Martin NE, Nguyen PL. Identification of comorbidities that place men at highest risk of death from androgen deprivation therapy before brachytherapy for prostate cancer. Brachytherapy. 2013 Sep-Oct; 12(5):415-21.

View in: PubMed

People

Explore

Similar Concepts

Top Journals